{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:49:41Z","timestamp":1761745781318},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,7]]},"DOI":"10.7759\/cureus.34745","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T21:38:57Z","timestamp":1675805937000},"source":"Crossref","is-referenced-by-count":2,"title":["A Systematic Review of How To Reduce Morbidity in HIV Patients With Cardiovascular Diseases"],"prefix":"10.7759","author":[{"given":"Namratha","family":"Pallipamu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sogand","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suvedha S","family":"Thiagaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Twisha S","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanmani","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X13666171129170046","article-title":"Cardiovascular disease in the setting of human immunodeficiency virus infection","volume":"14","author":"Pinto DS","year":"2018","unstructured":"Pinto DS, da Silva MJ. Cardiovascular disease in the setting of human immunodeficiency virus infection. Curr Cardiol Rev. 2018, 14:25-41. 10.2174\/1573403X13666171129170046","journal-title":"Curr Cardiol Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052504","article-title":"Atherosclerosis in HIV patients: what do we know so far?","volume":"23","author":"Poznyak AV","year":"2022","unstructured":"Poznyak AV, Bezsonov EE, Borisov EE, Grechko AV, Kartuesov AG, Orekhov AN. Atherosclerosis in HIV patients: what do we know so far?. Int J Mol Sci. 2022, 23:10.3390\/ijms23052504","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5501\/wjv.v4.i2.56","article-title":"Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs","volume":"4","author":"da Cunha J","year":"2015","unstructured":"da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World J Virol. 2015, 4:56-77. 10.5501\/wjv.v4.i2.56","journal-title":"World J Virol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202012_24033","article-title":"Integrase inhibitor-based antiretroviral treatments decrease oxidative stress caused by HIV infection","volume":"24","author":"Akkoyunlu Y","year":"2020","unstructured":"Akkoyunlu Y, Kocyigit A, Okay G, Guler EM, Aslan T. Integrase inhibitor-based antiretroviral treatments decrease oxidative stress caused by HIV infection. Eur Rev Med Pharmacol Sci. 2020, 24:12389-94. 10.26355\/eurrev_202012_24033","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/2050312120924892","article-title":"The association of nadir CD4-T cell count and endothelial dysfunction in a healthy HIV cohort without major cardiovascular risk factors","volume":"8","author":"Mogadam E","year":"2020","unstructured":"Mogadam E, King K, Shriner K, et al.. The association of nadir CD4-T cell count and endothelial dysfunction in a healthy HIV cohort without major cardiovascular risk factors. SAGE Open Med. 2020, 8:2050312120924892. 10.1177\/2050312120924892","journal-title":"SAGE Open Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1590\/1413-81232018245.16682017","article-title":"Risk factors for cardiovascular disease in HIV\/AIDS patients treated with highly active antiretroviral therapy (HAART) in the central-southern region of the state of Paran\u00e1 - Brazil","volume":"24","author":"Muller EV","year":"2019","unstructured":"Muller EV, Gimeno SG. Risk factors for cardiovascular disease in HIV\/AIDS patients treated with highly active antiretroviral therapy (HAART) in the central-southern region of the state of Paran\u00e1 - Brazil. Cien Saude Colet. 2019, 24:1903-14. 10.1590\/1413-81232018245.16682017","journal-title":"Cien Saude Colet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026631","article-title":"Cardiovascular disease and prevention among people living with HIV in South Florida","volume":"100","author":"Pyarali F","year":"2021","unstructured":"Pyarali F, Iordanov R, Ebner B, et al.. Cardiovascular disease and prevention among people living with HIV in South Florida. Medicine (Baltimore). 2021, 100:e26631. 10.1097\/MD.0000000000026631","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002161","article-title":"Association of HIV infection and antiretroviral therapy with sudden cardiac death","volume":"82","author":"Yen YF","year":"2019","unstructured":"Yen YF, Lai YJ, Chen YY, Lai HH, Chuang PH, Chen CC, Deng CY. Association of HIV infection and antiretroviral therapy with sudden cardiac death. J Acquir Immune Defic Syndr. 2019, 82:468-74. 10.1097\/QAI.0000000000002161","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001917","article-title":"Human immunodeficiency virus increases the risk of incident heart failure","volume":"80","author":"Yen YF","year":"2019","unstructured":"Yen YF, Ko MC, Yen MY, et al.. Human immunodeficiency virus increases the risk of incident heart failure. J Acquir Immune Defic Syndr. 2019, 80:255-63. 10.1097\/QAI.0000000000001917","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5830\/CVJA-2020-065","article-title":"Clinical and echocardiographic findings in a cross-sectional study of HIV-infected adults in Enugu, Nigeria","volume":"32","author":"Njoku PO","year":"2021","unstructured":"Njoku PO, Ejim EC, Anisiuba BC, Ike SO, Onwubere BJ. Clinical and echocardiographic findings in a cross-sectional study of HIV-infected adults in Enugu, Nigeria. Cardiovasc J Afr. 2021, 32:320-6. 10.5830\/CVJA-2020-065","journal-title":"Cardiovasc J Afr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.11648\/j.ccr.20190303.11","article-title":"HAART use and cardiovascular risk among HIV patients in Rivers State, Nigeria","volume":"3","author":"Oluwabunmi AA","year":"2019","unstructured":"Oluwabunmi AA, Nnedinma OS, James OO. HAART use and cardiovascular risk among HIV patients in Rivers State, Nigeria. Cardiol Cardiovasc Res. 2019, 3:45-51. 10.11648\/j.ccr.20190303.11","journal-title":"Cardiol Cardiovasc Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.12864","article-title":"Cardiovascular risks in Asian HIV-infected patients receiving boosted-protease inhibitor-based antiretroviral treatment","volume":"15","author":"Ounjaijean S","year":"2021","unstructured":"Ounjaijean S, Kulprachakarn K, Aurpibul L, et al.. Cardiovascular risks in Asian HIV-infected patients receiving boosted-protease inhibitor-based antiretroviral treatment. J Infect Dev Ctries. 2021, 15:289-96. 10.3855\/jidc.12864","journal-title":"J Infect Dev Ctries"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa425","article-title":"Endothelial dysfunction is related to monocyte activation in antiretroviral-treated people with HIV and HIV-negative adults in Kenya","volume":"7","author":"Temu TM","year":"2020","unstructured":"Temu TM, Polyak SJ, Zifodya JS, et al.. Endothelial dysfunction is related to monocyte activation in antiretroviral-treated people with HIV and HIV-negative adults in Kenya. Open Forum Infect Dis. 2020, 7:ofaa425. 10.1093\/ofid\/ofaa425","journal-title":"Open Forum Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420972855","article-title":"Assessment of atherosclerotic cardiovascular disease risks between people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting","volume":"32","author":"Tiarukkitsagul J","year":"2021","unstructured":"Tiarukkitsagul J, Sungkanuparph S. Assessment of atherosclerotic cardiovascular disease risks between people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting. Int J STD AIDS. 2021, 32:421-6. 10.1177\/0956462420972855","journal-title":"Int J STD AIDS"},{"key":"ref15","article-title":"HIV and cardiovascular disease: from insights to interventions","volume":"29","author":"Feinstein MJ","year":"2021","unstructured":"Feinstein MJ. HIV and cardiovascular disease: from insights to interventions. Top Antivir Med. 2021, 29:407-11.","journal-title":"Top Antivir Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2020.02.012","article-title":"Reducing cardiovascular risk among people living with HIV: rationale and design of the increasing statin prescribing in HIV behavioral economics Research (INSPIRE) randomized controlled trial","volume":"63","author":"Takada S","year":"2109","unstructured":"Takada S, Ober AJ, Currier JS, et al.. Reducing cardiovascular risk among people living with HIV: rationale and design of the increasing statin prescribing in HIV behavioral economics Research (INSPIRE) randomized controlled trial. Prog Cardiovasc Dis. 2109, 63:109-117. 10.1016\/j.pcad.2020.02.012","journal-title":"Prog Cardiovasc Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-017-0652-3","article-title":"HIV infection and risk of cardiovascular diseases beyond coronary artery disease","volume":"19","author":"Barnes RP","year":"2017","unstructured":"Barnes RP, Lacson JC, Bahrami H. HIV infection and risk of cardiovascular diseases beyond coronary artery disease. Curr Atheroscler Rep. 2017, 19:20. 10.1007\/s11883-017-0652-3","journal-title":"Curr Atheroscler Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201807-460OC","article-title":"Lung function, coronary artery disease, and mortality in HIV","volume":"16","author":"Chandra D","year":"2019","unstructured":"Chandra D, Gupta A, Fitzpatrick M, et al.. Lung function, coronary artery disease, and mortality in HIV. Ann Am Thorac Soc. 2019, 16:687-97. 10.1513\/AnnalsATS.201807-460OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.11.029","article-title":"Coronary artery disease manifestations in HIV: what, how, and why","volume":"35","author":"Sinha A","year":"2019","unstructured":"Sinha A, Feinstein MJ. Coronary artery disease manifestations in HIV: what, how, and why. Can J Cardiol. 2019, 35:270-9. 10.1016\/j.cjca.2018.11.029","journal-title":"Can J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2174\/1570162x12666140402100959","article-title":"Oxidative stress in HIV patients receiving antiretroviral therapy","volume":"12","author":"Sharma B","year":"2014","unstructured":"Sharma B. Oxidative stress in HIV patients receiving antiretroviral therapy. Curr HIV Res. 2014, 12:13-21. 10.2174\/1570162x12666140402100959","journal-title":"Curr HIV Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.06.001","article-title":"Antiretroviral therapy: current drugs","volume":"28","author":"Pau AK","year":"2014","unstructured":"Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014, 28:371-402. 10.1016\/j.idc.2014.06.001","journal-title":"Infect Dis Clin North Am"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049330","article-title":"Effect of aspirin on HIV disease progression among HIV-infected individuals initiating antiretroviral therapy: study protocol for a randomised controlled trial","volume":"11","author":"Mwakyandile T","year":"2021","unstructured":"Mwakyandile T, Shayo G, Mugusi S, et al.. Effect of aspirin on HIV disease progression among HIV-infected individuals initiating antiretroviral therapy: study protocol for a randomised controlled trial. BMJ Open. 2021, 11:e049330. 10.1136\/bmjopen-2021-049330","journal-title":"BMJ Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.8.844","article-title":"Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients","volume":"20","author":"Cantudo-Cuenca MR","year":"2014","unstructured":"Cantudo-Cuenca MR, Jim\u00e9nez-Gal\u00e1n R, Almeida-Gonzalez CV, Morillo-Verdugo R. Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients. J Manag Care Spec Pharm. 2014, 20:844-50. 10.18553\/jmcp.2014.20.8.844","journal-title":"J Manag Care Spec Pharm"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-021-01563-0","article-title":"Factors affecting statin uptake among people living with HIV: primary care provider perspectives","volume":"22","author":"Ober AJ","year":"2021","unstructured":"Ober AJ, Takada S, Zajdman D, et al.. Factors affecting statin uptake among people living with HIV: primary care provider perspectives. BMC Fam Pract. 2021, 22:215. 10.1186\/s12875-021-01563-0","journal-title":"BMC Fam Pract"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238575","article-title":"A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV","volume":"15","author":"Negredo E","year":"2020","unstructured":"Negredo E, Jim\u00e9nez M, Puig J, et al.. A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS One. 2020, 15:e0238575. 10.1371\/journal.pone.0238575","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.12.016","article-title":"Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)","volume":"212","author":"Grinspoon SK","year":"2019","unstructured":"Grinspoon SK, Fitch KV, Overton ET, et al.. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019, 212:23-35. 10.1016\/j.ahj.2018.12.016","journal-title":"Am Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/119116-a-systematic-review-of-how-to-reduce-morbidity-in-hiv-patients-with-cardiovascular-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:33Z","timestamp":1707508713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/119116-a-systematic-review-of-how-to-reduce-morbidity-in-hiv-patients-with-cardiovascular-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.34745","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,7]]}}}